Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Always free.

Therapies 137

Therapies Virus DNA Clinical Trials 137

Drug Target Review

MAY 26, 2025

With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drug developers with the tools, insights, and support needed to advance their therapies from concept to clinic. We are driving rapid analytics to support the release of cell and gene therapies and other biologics.

Drug Development 52

Drug Development Drugs Therapies Pharmaceuticals 52

The Anticancer Fund

JUNE 7, 2022

However, patients treated with subsequent therapies, including rechallenge with previous treatments some showed very encouraging responses - intriguingly suggesting the combination treatment may work to reverse drug resistance in this population with few other options.

Drugs 40

Drugs Clinical Trials Trials Treatment 40

Agency IQ

JULY 12, 2024

BY LAURA DIANGELO, MPH | JUL 10, 2024 3:47 PM CDT Regulatory background: The FDA is responsible for overseeing information about regulated products. The FDA is responsible for ensuring that medical products are adequately labeled in accordance with federal regulations, including the product’s “intended use” and relevant safety information.

FDA 40

FDA Regulations Production Science 40

The Pharma Data

MAY 13, 2021

Unfortunately, I learned the hard way that the “Big Pharma” companies don’t care about their patients. That’s right, if you’re suffering from pain, then “Red Light Therapy” is about to become your new best friend. But what actually is “Red Light Therapy”? You see, Red Light Therapy is expensive.

Pharmacy 52

Pharmacy Doctors Production Therapies 52

Drug Target Review

MARCH 13, 2025

The journey from distrust to collaboration among industry, academia and regulators will expedite integration, minimise clinical failures and enhance economic sustainability. Techbio companies have initiated this approach. FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine.

Drug Development 59

Drug Development Science Clinical Trials Drugs 59

The Pharma Data

DECEMBER 30, 2020

The reason for this is still not understood and many regulators may want it to be explained before authorizing it for broader use. It is a strong potential player in the gene therapy space. billion, Regenxbio is also a gene therapy company. It also is developing three other gene therapies for rare neurological diseases.

Vaccine 52

Vaccine FDA Trials Therapies 52